OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Advance planning is essential to ensure a reliable supply for parenteral drug packaging
Consistency, robustness, and API-excipient understanding are essential for successful drug release.
Despite challenges caused by COVID-19, M&A activity in life sciences is recovering well.
Intelligent analytical tools detect impurities in small-molecule drug ingredients.
Okra gum serves as a polymer for oral drug formulations.
Microbial experts should employ proactive practices on the manufacturing floor.
Next Big COVID Challenge: Vaccines for Little Kids
Pharma strategizes to reduce its environmental footprint while optimizing output.
September 23, 2021
The first and only approved antibody-drug conjugate for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy receives accelerated approval by FDA.
Boehringer Ingelheim to develop novel cancer therapies by leveraging Abexxa’s breakthrough antibody-based drugs.
In an amendment to their existing contract manufacturing agreement, Celsian and Poly Pharm expand GEN-1 program collaboration to add clinical and commercial batches of investigational vaccine.
Verrica Pharmaceuticals receives CRL from FDA identifying deficiencies at a facility of a CMO for its NDA for VP-102.
The research collaboration between AstraZeneca and VaxEquity aims to discover and develop self-amplifying RNA therapeutics.
The FDA has amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine to allow a single booster dose to several high-risk populations.
New data finds J&J COVID-19 vaccine and booster to provide increased protection against COVID-19.
September 22, 2021
Celularity and Oncternal’s collaboration will focus on therapeutics targeting Orphan Receptor 1, which is linked to aggression and survival in solid tumor cells.
Lonza’s investment in its Stein and Basel facilities in Switzerland aims to expand its overall drug product development and manufacturing services.
Novartis’ acquisition of Arctos Medical could lead to significant advancements in optogenetic therapies for patients with vision loss.